An Open-label Extension Study of PSMA ADC 2301 in mCRPC
NCT02020135
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
9
Enrollment
INDUSTRY
Sponsor class
Conditions
Prostate Cancer
Interventions
DRUG:
PSMA ADC
Sponsor
Progenics Pharmaceuticals, Inc.